At the WCI Summit in November, researchers shared some of the novel techniques that they are using to improve the human ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

A trial has shown boosting diet with supplements could halt tumour growth in prostate cancer patients - opening the door to a ...

They plan to run similar trials on seven more patients over the next three years, backed by $4 million from the National ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

An 82-year-old former TV presenter who still plays the drums in the West Midlands after successful cancer treatment is ...

The licensing agreement, which includes a big upfront payment of $650 million and milestone payments of up to $4.95 billion, ...

Supercharging immune cells could provide an effective way to tackle cancer, according to new research by scientists in ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally ...

Randomness inside cells can decide whether a cancer returns after chemotherapy or whether an infection survives antibiotics.

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...